What are the functions and efficacy of ruxolitinib tablets/ruxolitinib?

Ruxolitinib is a drug widely used to treat specific diseases and belongs to the kinase inhibitor category. It is mainly used in patients who are ineffective or intolerant to other treatments such as hydroxyurea, mainly including myelofibrosis, polycythemia vera and other diseases, and can be used to treat graft-versus-host disease that is refractory to steroid therapy.

Ruxolitinib is an anti-tumor drug whose mechanism of action is by inhibitingJAK (Janus kinase)-induced phosphorylation of signal transducer and activator of transcription (STAT). This drug inhibits the proliferation of malignant cells, induces their apoptosis, and reduces the levels of pro-inflammatory cytokines in plasma. Ruxolitinib mainly works by inhibiting the phosphorylation of STAT3, which is a marker of JAK activity. Ruxolitinib is able to achieve inhibition of STAT3 phosphorylation within 2 hours after administration, and this inhibition returns to near baseline 10 hours after administration.

In clinical trials, ruxolitinib has been shown to potentially reduce symptoms of splenomegaly and improve symptoms of myelofibrosis. In mouse models of myeloproliferative neoplasms, ruxolitinib was associated with prolonged survival. In addition, ruxolitinib can also inhibit the activity of mutant and wild-type JAK2. However, ruxolitinib sensitivity is reduced in patients harboring the JAK2 V617F mutation (usually found in approximately 50% of myelofibrosis patients), which may also be related to drug resistance.

In summary, ruxolitinib is a drug used to treat specific diseases. It works mainly by inhibitingJAK-induced phosphorylation of signal transducers and transcriptional activators. It has been clinically shown to reduce symptoms, improve survival and suppress specific genetic mutations.